BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 28057036)

  • 1. Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system.
    Katoh N; Soda I; Tamamura H; Takahashi S; Uchinami Y; Ishiyama H; Ota K; Inoue T; Onimaru R; Shibuya K; Hayakawa K; Shirato H
    Radiat Oncol; 2017 Jan; 12(1):3. PubMed ID: 28057036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor volume change with stereotactic body radiotherapy (SBRT) for early-stage lung cancer: evaluating the potential for adaptive SBRT.
    Bhatt AD; El-Ghamry MN; Dunlap NE; Bhatt G; Harkenrider MM; Schuler JC; Zacarias A; Civelek AC; Pan J; Rai SN; Woo SY
    Am J Clin Oncol; 2015 Feb; 38(1):41-6. PubMed ID: 24513663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy.
    Yamamoto T; Kadoya N; Shirata Y; Koto M; Sato K; Matsushita H; Sugawara T; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Ito K; Katagiri Y; Takeda K; Jingu K
    Radiat Oncol; 2015 Feb; 10():35. PubMed ID: 25886315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer.
    Inoue T; Katoh N; Onimaru R; Shimizu S; Tsuchiya K; Suzuki R; Sakakibara-Konishi J; Shinagawa N; Oizumi S; Shirato H
    Radiat Oncol; 2013 Mar; 8():69. PubMed ID: 23518013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
    Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
    Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation.
    Guckenberger M; Wulf J; Mueller G; Krieger T; Baier K; Gabor M; Richter A; Wilbert J; Flentje M
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):47-54. PubMed ID: 18977095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
    Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
    Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
    Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
    Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
    Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.
    Xia T; Li H; Sun Q; Wang Y; Fan N; Yu Y; Li P; Chang JY
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):117-25. PubMed ID: 16765528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors.
    Parker SM; Siochi RA; Wen S; Mattes MD
    Pract Radiat Oncol; 2019 Jan; 9(1):e90-e97. PubMed ID: 30267899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CyberKnife radiosurgery for stage I lung cancer: results at 36 months.
    Brown WT; Wu X; Fayad F; Fowler JF; Amendola BE; García S; Han H; de la Zerda A; Bossart E; Huang Z; Schwade JG
    Clin Lung Cancer; 2007 Sep; 8(8):488-92. PubMed ID: 17922973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience.
    Stephans KL; Djemil T; Reddy CA; Gajdos SM; Kolar M; Mason D; Murthy S; Rice TW; Mazzone P; Machuzak M; Mekhail T; Videtic GM
    J Thorac Oncol; 2009 Aug; 4(8):976-82. PubMed ID: 19633473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors.
    Trakul N; Chang CN; Harris J; Chapman C; Rao A; Shen J; Quinlan-Davidson S; Filion EJ; Wakelee HA; Colevas AD; Whyte RI; Dieterich S; Maxim PG; Hristov D; Tran P; Le QT; Loo BW; Diehn M
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):231-7. PubMed ID: 22381907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.
    Takeda A; Sanuki N; Kunieda E; Ohashi T; Oku Y; Takeda T; Shigematsu N; Kubo A
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):442-8. PubMed ID: 18990507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.